COVID-19 and chronic obstructive pulmonary disease: what is known about the unknown
The article reviews 60 publications and addresses key aspects of concurrent COVID-19 and chronic obstructive pulmonary disease (COPD). It presents data stating that COPD patients have higher expression of the receptor of angiotensin-converting enzyme 2 in the lungs and this may contribute to a great...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
New Terra Publishing House
2021-03-01
|
| Series: | Туберкулез и болезни лёгких |
| Subjects: | |
| Online Access: | https://www.tibl-journal.com/jour/article/view/1505 |
| _version_ | 1797702987073716224 |
|---|---|
| author | E. S. Ovsyannikov S. N. Avdeev A. V. Budnevskiy E. S. Drobysheva A. Ya. Kravchenko |
| author_facet | E. S. Ovsyannikov S. N. Avdeev A. V. Budnevskiy E. S. Drobysheva A. Ya. Kravchenko |
| author_sort | E. S. Ovsyannikov |
| collection | DOAJ |
| description | The article reviews 60 publications and addresses key aspects of concurrent COVID-19 and chronic obstructive pulmonary disease (COPD). It presents data stating that COPD patients have higher expression of the receptor of angiotensin-converting enzyme 2 in the lungs and this may contribute to a greater susceptibility to COVID-19. In COPD, signs of endothelial cell dysfunction and tendency to thrombus formation have been identified which can present the risk of unfavorable outcomes of COVID-19. Cohort study data do not confirm that COPD patients are more susceptible to SARS-CoV-2 infection, but their clinical outcomes of COVID-19 appear to be worse including the need for mechanical ventilation and lethality. There is no clinical evidence about the role of inhaled glucocorticosteroids used to manage COPD in the development and course of COVID-19. |
| first_indexed | 2024-03-12T04:57:55Z |
| format | Article |
| id | doaj.art-a36bad2e09934efe8b7296b906cee35f |
| institution | Directory Open Access Journal |
| issn | 2075-1230 2542-1506 |
| language | Russian |
| last_indexed | 2024-03-12T04:57:55Z |
| publishDate | 2021-03-01 |
| publisher | New Terra Publishing House |
| record_format | Article |
| series | Туберкулез и болезни лёгких |
| spelling | doaj.art-a36bad2e09934efe8b7296b906cee35f2023-09-03T09:14:38ZrusNew Terra Publishing HouseТуберкулез и болезни лёгких2075-12302542-15062021-03-0199261510.21292/2075-1230-2021-99-2-6-151502COVID-19 and chronic obstructive pulmonary disease: what is known about the unknownE. S. Ovsyannikov0S. N. Avdeev1A. V. Budnevskiy2E. S. Drobysheva3A. Ya. Kravchenko4ФГБОУ ВО «Воронежский государственный медицинский университет им. Н. Н. Бурденко» МЗ РФФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова МЗ РФ (Сеченовский университет)ФГБОУ ВО «Воронежский государственный медицинский университет им. Н. Н. Бурденко» МЗ РФФГБОУ ВО «Воронежский государственный медицинский университет им. Н. Н. Бурденко» МЗ РФФГБОУ ВО «Воронежский государственный медицинский университет им. Н. Н. Бурденко» МЗ РФThe article reviews 60 publications and addresses key aspects of concurrent COVID-19 and chronic obstructive pulmonary disease (COPD). It presents data stating that COPD patients have higher expression of the receptor of angiotensin-converting enzyme 2 in the lungs and this may contribute to a greater susceptibility to COVID-19. In COPD, signs of endothelial cell dysfunction and tendency to thrombus formation have been identified which can present the risk of unfavorable outcomes of COVID-19. Cohort study data do not confirm that COPD patients are more susceptible to SARS-CoV-2 infection, but their clinical outcomes of COVID-19 appear to be worse including the need for mechanical ventilation and lethality. There is no clinical evidence about the role of inhaled glucocorticosteroids used to manage COPD in the development and course of COVID-19.https://www.tibl-journal.com/jour/article/view/1505covid-19хроническая обструктивная болезнь легких |
| spellingShingle | E. S. Ovsyannikov S. N. Avdeev A. V. Budnevskiy E. S. Drobysheva A. Ya. Kravchenko COVID-19 and chronic obstructive pulmonary disease: what is known about the unknown Туберкулез и болезни лёгких covid-19 хроническая обструктивная болезнь легких |
| title | COVID-19 and chronic obstructive pulmonary disease: what is known about the unknown |
| title_full | COVID-19 and chronic obstructive pulmonary disease: what is known about the unknown |
| title_fullStr | COVID-19 and chronic obstructive pulmonary disease: what is known about the unknown |
| title_full_unstemmed | COVID-19 and chronic obstructive pulmonary disease: what is known about the unknown |
| title_short | COVID-19 and chronic obstructive pulmonary disease: what is known about the unknown |
| title_sort | covid 19 and chronic obstructive pulmonary disease what is known about the unknown |
| topic | covid-19 хроническая обструктивная болезнь легких |
| url | https://www.tibl-journal.com/jour/article/view/1505 |
| work_keys_str_mv | AT esovsyannikov covid19andchronicobstructivepulmonarydiseasewhatisknownabouttheunknown AT snavdeev covid19andchronicobstructivepulmonarydiseasewhatisknownabouttheunknown AT avbudnevskiy covid19andchronicobstructivepulmonarydiseasewhatisknownabouttheunknown AT esdrobysheva covid19andchronicobstructivepulmonarydiseasewhatisknownabouttheunknown AT ayakravchenko covid19andchronicobstructivepulmonarydiseasewhatisknownabouttheunknown |